tiprankstipranks

Peter Powchik Insider Profile

4 Followers
Peter Powchik, SVP Clinical Development & Reg at Regeneron, holds 32.28K shares in Regeneron (Ticker: REGN), holds 225.86K shares in Vaxxinity Inc (Ticker: VAXX). Most recently, Peter Powchik Bought ― shares of Regeneron on Dec 16, 2015 for an estimated value of 99.95K.
tipranks
Peter Powchik

Peter Powchik
Regeneron (REGN)
SVP Clinical Development & Reg

Ranked #43,237 out of 99,024 Corporate Insiders

Profitable Transactions

67%
2 out of 3 Profitable Transactions

Average Return

+3.40%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$32M
99.93%
0.07%
A breakdown of Peter Powchik's holdings

Insider Roles

Regeneron
(REGN)
SVP Clinical Development & Reg
Vaxxinity Inc
(VAXX)
Director
Roles that Peter Powchik holds in companies

Most Profitable Insider Trade

Stock:
Regeneron
(REGN)
Rating:Informative Buy
Date:Dec 22, 2014 - Dec 22, 2015
Return:+39.60%
The most profitable trade made by Peter Powchik

Peter Powchik's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Regeneron
Dec 16, 2015
SVP Clinical Development & Reg
Informative Buy
99.95K
$31.87M
Vaxxinity Inc
Director
$21.23K
List of latest transactions for each holding click on a transaction to see Peter Powchik's performance on stock

Peter Powchik insider profile FAQ

What is the percentage of profitable transactions made by Peter Powchik?
The percentage of profitable transactions made by Peter Powchik is 67%.
    What is the average return per transaction made by Peter Powchik?
    The average return per transaction made by Peter Powchik is 3.40%.
      What stocks does Peter Powchik hold?
      Peter Powchik holds: REGN, VAXX stocks.
        What was Peter Powchik’s latest transaction?
        Peter Powchik latest transaction was an Informative Buy of $99.95K.
          What was Peter Powchik's most profitable transaction?
          Peter Powchik’s most profitable transaction was an Informative Buy of REGN stock on December 22, 2014. The return on the trade was 39.60%.
            What is Peter Powchik's role in Regeneron?
            Peter Powchik's role in Regeneron is SVP Clinical Development & Reg.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.